Evidence map›Paper›PMID 10952619›Full record

ArticleAntimicrobial agents and chemotherapy2000

Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis.

I Katsarolis, A Pefanis, D Iliopoulos, P Siaperas, P Karayiannakos, H Giamarellou

Open access · greenAbstract readComparative Study
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 84% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

I Katsarolis4th Department of Medicine, Sismanoglion General Hospital, Athens, Greece. aikat@ath.forthnet.gr
A Pefanis
D Iliopoulos
P Siaperas
P Karayiannakos
H Giamarellou
Sismanoglio General Hospital · GRSotiria General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Single-dose trovafloxacin (15 mg/kg given intravenously [i.v.]) and ampicillin (40 mg/kg given i.v.) protected 38 and 33% of animals challenged with an ampicillin-tolerant strain of Streptococcus oralis, respectively. As a double-dose regimen, trovafloxacin afforded total protection (100%; P < 0.001 versus controls). Trovafloxacin is the first fluoroquinolone effective in preventing experimental streptococcal endocarditis.

Indexed as

FluoroquinolonesAmpicillinAnimalsAntibiotic ProphylaxisAnti-Infective AgentsAortic ValveDisease Models, AnimalEndocarditis, BacterialFemaleHeart Valve DiseasesMicrobial Sensitivity TestsNaphthyridinesPenicillinsRabbitsStreptococcal InfectionsStreptococcusAmpicillinAnti-Infective AgentsFluoroquinolonesNaphthyridinesPenicillinstrovafloxacin

Identifiers

PMID10952619
PMCPMC90109
OpenAlexW2124780569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.